Identification of Biomarkers for Patients with Vascular Anomalies

Purpose: To identify biomarkers in patients diagnosed with a vascular anomaly*.

Who is eligible: Any participant with a diagnosed vascular anomaly* that are currently not on treatment for the condition and are having labs (blood) drawn as standard of care.

What the study involves: When the participant undergoes a routine lab blood draw, we ask for a serum sample to be sent to our lab for use in our research identifying biomarkers. Serum samples can be sent once treatment is started, but to participate in the study a pre-treatment serum sample is required.

Why participate: Identifying specific biomarkers (a non-invasive blood test) is safer and an easier option used to diagnose a vascular anomaly and may avoid obtaining a tissue biopsy which can worsen the disease.

***Vascular anomalies included**: Generalized Lymphatic Anomaly (**GLA**), Gorham-Stout Disease (**GSD**), Kaposiform Hemangioendothelioma (**KHE**), Kaposiform Lymphangiomatosis (**KLA**), Klippel Trenaunay Syndrome (**KT**), Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi Syndrome (**CLOVES**)

FOR MORE INFORMATION CALL OR EMAIL
Megan Metcalf at 513-803-2606
hvmcresearch@cchmc.org
Principal Investigator: Timothy Le Cras, PhD.
Cincinnati Children's Hospital Medical Center, IRB 2015-2189
ClinicalTrials.gov Identifier: NCT03001180

V23FEB2021